Pharmacokinetic enhancers in HIV therapeutics.

Pharmacokinetic enhancers in HIV therapeutics.

Item
http://www.wikidata.org/entity/Q38244014
Potential drug interactions in patients given antiretroviral therapy.Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroMechanisms and Consequences of Drug-Drug Interactions.Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.
P2860

Pharmacokinetic enhancers in HIV therapeutics.

Item
http://www.wikidata.org/entity/Q38244014
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Pharmacokinetic enhancers in HIV therapeutics.
@en
type
label
Pharmacokinetic enhancers in HIV therapeutics.
@en
prefLabel
Pharmacokinetic enhancers in HIV therapeutics.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P921
P356
P1433
P1476
Pharmacokinetic enhancers in HIV therapeutics.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P921